“INDISCRIMINATE USE OF GLP-1 ANALOGUES, SUCH AS SEMAGLUTIDE (OZEMPIC®), FOR AESTHETIC PURPOSES AND MULTIDISCIPLINARY ACTION IN CARE AND RISK PREVENTION”, EIC, pp. 342–356, Oct. 2025, Accessed: Feb. 20, 2026. [Online]. Available: https://periodicos.newsciencepubl.com/editoraimpacto/article/view/9073